Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Raises the question of whether the use of composite endpoints in clinical trials sacrifices clinical relevance for statistical significance.
In selecting and defining composite end points in clinical trials, are we trading off clinical significance for statistical significance?
No takes yet. Share an insight, caveat, or question.
Dominic Y. Leung (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: